Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
Adult
Aged
Antineoplastic Agents, Immunological
/ therapeutic use
Bevacizumab
/ therapeutic use
Brain Neoplasms
/ diagnostic imaging
Diffusion Magnetic Resonance Imaging
/ methods
Female
Glioblastoma
/ diagnostic imaging
Humans
Image Interpretation, Computer-Assisted
Male
Middle Aged
Neoplasm Recurrence, Local
/ diagnostic imaging
Treatment Outcome
ADC
Bevacizumab
Glioblastoma
RANO
Radiographic pseudoresponse
Journal
Journal of neuroradiology = Journal de neuroradiologie
ISSN: 0150-9861
Titre abrégé: J Neuroradiol
Pays: France
ID NLM: 7705086
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
20
06
2017
revised:
16
03
2018
accepted:
21
04
2018
pubmed:
8
5
2018
medline:
12
2
2019
entrez:
8
5
2018
Statut:
ppublish
Résumé
Response Assessment in Neuro-Oncology Criteria (RANO), are used to asses response to first-line treatment of glioblastoma (GBM). Differentiation between response and pseudoresponse under treatment with Bevacizumab (BVZ) remains challenging. This study evaluates ADC changes in patients with radiographic pseudoresponse under treatment with (BVZ). Patients (n=40) with recurrent GBM under-treatment with BVZ underwent MRI before, two and four months after treatment with BVZ. In patients with radiological pseudoresponse (n=11), ADC analyses were performed. Areas with decreasing T1 contrast enhancement (CE) and FLAIR signal decrease were manually selected and compared to size and position matched healthy contralateral brain parenchyma. Histogram based ADC (10 Treatment of GBM with BVZ leads to a decrease of ADC values in areas of pre-treatment T1-CE/FLAIR signal hyperintensity to levels of comparable with normal brain tissue. ADC values remained stable, even when progressive tumor growth was reported.
Sections du résumé
BACKGROUND
BACKGROUND
Response Assessment in Neuro-Oncology Criteria (RANO), are used to asses response to first-line treatment of glioblastoma (GBM). Differentiation between response and pseudoresponse under treatment with Bevacizumab (BVZ) remains challenging. This study evaluates ADC changes in patients with radiographic pseudoresponse under treatment with (BVZ).
METHODS
METHODS
Patients (n=40) with recurrent GBM under-treatment with BVZ underwent MRI before, two and four months after treatment with BVZ. In patients with radiological pseudoresponse (n=11), ADC analyses were performed. Areas with decreasing T1 contrast enhancement (CE) and FLAIR signal decrease were manually selected and compared to size and position matched healthy contralateral brain parenchyma.
RESULTS
RESULTS
Histogram based ADC (10
CONCLUSION
CONCLUSIONS
Treatment of GBM with BVZ leads to a decrease of ADC values in areas of pre-treatment T1-CE/FLAIR signal hyperintensity to levels of comparable with normal brain tissue. ADC values remained stable, even when progressive tumor growth was reported.
Identifiants
pubmed: 29733920
pii: S0150-9861(17)30349-8
doi: 10.1016/j.neurad.2018.04.002
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-43Informations de copyright
Copyright © 2018. Published by Elsevier Masson SAS.